| Autor: |
Yamazaki T; The Jikei University School of Medicine., Kimura T; The Jikei University School of Medicine., Kayano S; The Jikei University School of Medicine., Kurauchi T; The Jikei University School of Medicine., Ito K; The Jikei University School of Medicine., Yasue K; The Jikei University School of Medicine., Onuma H; The Jikei University School of Medicine., Yanagisawa T; The Jikei University School of Medicine., Murakami M; The Jikei University School of Medicine., Yamada H; The Jikei University School of Medicine., Egawa S; The Jikei University School of Medicine. |
| Jazyk: |
japonština |
| Zdroj: |
Hinyokika kiyo. Acta urologica Japonica [Hinyokika Kiyo] 2021 Dec; Vol. 67 (12), pp. 521-524. |
| DOI: |
10.14989/ActaUrolJap_67_12_521 |
| Abstrakt: |
We compared brain metastasis of renal cell carcinoma (RCC) in patients who received tyrosine kinase inhibitors (TKIs) ; 17 received local therapy, while 16 did not. The median survival rate was 19 months in the local therapy group and 11 months in the tyrosine kinase inhibitor alone group, showing no significant difference (p＝0.52). Symptoms such as paralysis, headache, and dysarthria occurred due to brain metastasis. These symptoms improved in 8 out of 10 patients in the local therapy group. There were no cases of grade 3 or higher complications due to local therapy. Although local therapy did not prolong the overall survival, an improvement in symptoms was observed, suggesting that it is acceptable as palliative treatment. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
